Table I.
Clinicopathological characteristics of the patients.
| A, All cases, n=482 | |
|---|---|
| Characteristic | Number/mean (SD) |
| Sex, female/male | |
| Female | 281 |
| Male | 201 |
| Age, years | 66.29 (14.3) |
| Height, m | 1.584 (0.096) |
| Body weight, kg | 60.003 (14.142) |
| BMI, kg/m2 | 23.79 (4.6) |
| Liver disease | |
| AIH | 24 |
| AL | 31 |
| HBV | 97 |
| HCV | 18 |
| Complicated malignancy disease | |
| CCC | 1 |
| HCC | 12 |
| Gastric cancer | 2 |
| Pancreatic cancer | 5 |
| RCC | 1 |
| Diabetes mellitus | 80 |
| Total bilirubin, mg/dla | 1.068 (3.589) |
| Albumin, g/dlb | 4.324 (3.145) |
| Prothrombin time, %c | 102.65 (17.8) |
| Prothrombin time, INRd | 1.007 (0.159) |
| Hepatic encephalopathyi | |
| 1 | 477 |
| 2 | 5 |
| 3 | 0 |
| Ascitesi | |
| 1 | 467 |
| 2 | 14 |
| 3 | 1 |
| Cr, mg/le | 0.93 (0.996) |
| Cr-eGFR, ml/min/1.73 m2 | 67.51 (20.636) |
| CysC, mg/f | 1.188 (0.875) |
| CysC-eGFR, ml/min/1.73 m2 | 68.05 (25.731) |
| Platelets, x104/µlg | 18.66 (7.1) |
| AST, U/lh | 42.317 (57.25) |
| AL, U/l | 38.8 (52.6) |
| CPS | 5.158 (0.642) |
| CPG | |
| A | 463 |
| B | 17 |
| C | 2 |
| MELD | 7.574 (2.428) |
| FIB-4 | 2.901 (2.597) |
| ALBI | -2.923 (2.671) |
| ALBIG | 370/103/9 |
| 1 | |
| 2 | |
| 3 | |
| GS, kg | 19.76 (9.57) |
| GS low/normal | |
| Low | 285 |
| Normal | 197 |
| Sarcopenia Index | 77.02 (30.7) |
| CBMM | 35.54 (8.39) |
| Sarcopenia/normal, CBMM | 168/310 |
| deGFR | -0.109 (18.55) |
| SARC-F | 1.589 (2.05) |
| Sarcopenia/normal, SARC-F | 85/397 |
| B, Patients who underwent an evaluation of body composition, n=273 | |
| Factors | Number/mean (SD) |
| SM, cm2 | 104.4 (27.08) |
| IMAT, cm2 | 7.356 (0.445) |
| VAT, cm2 | 112.86 (88.68) |
| SAT, cm2 | 129.92 (82.32) |
| MA, HU | 30.21 (7.491) |
| SMI, cm2/m2 | 41.42 (8.167) |
| Low SMI/normal | 120/153 |
| Sarcopenia | 96 |
aTotal bilirubin normal range, 0.3-1.2;
balbumin normal range, 3.8-5.2;
cprothrombin time (%), normal range 70-130 and INR normal range, 0.85-1.15;
dCr normal range males, 0.61-1.04 and females 0.47-0.79;
eCysC normal range males, 0.63-0.95 and females 0.56-0.87;
fplatelets normal range males, 13.1-36.2 and females, 13-36.9;
gAST, 10-40;
hALT, 5-40.
iAscites and hepatic encephalopathy grades: 1, absent; 2 controllable; and 3, uncontrollable. BMI, body mass index; AIH, autoimmune hepatitis; AL, ; HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalized ratio; Cr, creatinine; eGFRP, estimated glomerular filtration rate; CysC, cystatic C; AST, aspartate aminotransferase; AL, alcoholic liver disease; CPS, Child-Pugh score; CPG, CPS grade; MELD, The model for end-stage liver disease; FIB-4, fibrosis -4; ALBI, albumin bilirubin index; ALBIG, ALBI grade; GS, grip strength; CBMM, calculated body muscle mass; deGFR, difference in eGFPR; SM, skeletal muscle; IMAT, intramuscular adipose tissue; VAT, visceral adipose tissue; SAT, subcutaneous; MA, muscle attenuation; HU, Housefield units; SMI, SM index; CCC, cholangiocellular carcinoma; HCC, hepatocellular carcinoma; RCC, renal cell carcinoma; SD, standard deviation.